A specialized R&D company developing next-generation trace chemical detection and breath-based diagnostic instruments. We combine deep expertise in spectroscopy, AI inference, and instrument engineering to solve detection problems that conventional technology cannot.
AATG LLC is a focused specialist R&D company headquartered in New Jersey. The founder has close to 30 years of combined experience in field threat detection, trace chemical sensing, and defense instrument development.
Our work is grounded in one conviction: that the detection instruments operators and clinicians depend on in life-safety situations must be better than what is currently available. We build technology that closes the gap between what is needed and what exists — not by incremental improvement of existing designs, but by applying a fundamentally different approach.
We do not build products that are "good enough." We build products that close a documented, consequential capability gap using defensible, peer-reviewed science as the foundation — and then subject those claims to rigorous validation before any government or clinical customer commitment.
Every design decision is driven by asking: what does the operational scenario actually require? We choose methods and technologies that fit the problem — not the ones that are most familiar. Where that leads us to unconventional approaches, we document the reasoning and subject it to adversarial review.
We do not make performance claims until we have data. All sensitivity claims in our publications and briefings are anchored to peer-reviewed published results. Where empirical data does not yet exist, we say so explicitly — and we describe the validation plan that will generate it.
Our core proprietary AI inference architecture was not designed for defense and then applied to medicine. It was validated independently in a demanding clinical VOC detection application before being brought to the CWA detection problem. Real-world cross-domain performance is the strongest evidence that the science is real.
Each competency reflects sustained investment over many years — not recently acquired for a specific program, but developed as core organizational capability.
Deep expertise in proprietary optical detection and sensing for trace gas detection. Includes thermal pre-concentration and advanced signal processing configurations. Detection methodology grounded in published, peer-reviewed research.
Design and implementation of proprietary AI inference engines for chemical identification under open-world conditions. Expertise in calibrated confidence scoring, mixture analysis, and unknown compound characterization — capabilities that conventional chemometric methods cannot provide.
Nearly three decades of experience in CWA detection methodology, instrument characterization, and field deployment considerations. Prior collaboration with researchers at Edgewood Chemical Biological Center (ECBC) on CWA detection methodology. Deep understanding of the operational constraints that laboratory instruments do not model.
Validated methodology for detecting volatile organic compound (VOC) biomarkers in exhaled breath for cancer diagnostics. The breath matrix — complex, variable, and biologically meaningful — is a more demanding analytical challenge than field air sampling. This work validates the same proprietary detection architecture deployed in our defense platform.
Full-stack hardware development from optical breadboard through production prototype: sensor assembly, sample pre-concentration, and embedded electronics and firmware. Specific expertise in size, weight, and power optimization for handheld and UAV-payload applications.
Familiarity with SBIR/STTR program structure and application requirements. Experience with government technical review and documentation standards. Understanding of CWMD and MCDC consortium engagement pathways and the validation requirements they impose on development-stage detection platforms.
Everything we present to government customers and technical reviewers is grounded in documented, independently verifiable work.
Prior research collaboration with scientists at Edgewood Chemical Biological Center (ECBC) on CWA detection methodology. This work, reflected in publications and field detection reference materials, provides the government-validated scientific foundation for the r-Guard™ detection approach. Full details available to qualified partners under NDA.
Detection methodology anchored in peer-reviewed spectroscopy literature. All sensitivity claims traceable to published experimental data — not internal projections or unverified modelling. Reference list available under NDA.
The proprietary AI inference architecture was independently validated in a demanding clinical VOC detection application before r-Guard™ development began. This cross-domain validation is the strongest evidence of real-world AI performance.
Detection methodology, instrument configuration, signal processing architecture, and AI inference pipeline are IP protected. Full documentation available to qualified partners under NDA.
Core methodology appears in field detection reference texts. Work co-authored with Edgewood Chemical Biological Center (ECBC) researchers. Available to government partners upon NDA execution.
SBIR Phase I/II applications actively being prepared targeting DoD CWMD and related programs. MCDC consortium engagement planned. Government acquisition pathway well-understood.
The same proprietary detection architecture — advanced optical detection, sample preparation, and AI inference — drives both AATG product platforms. Validated cross-domain, de-risked by design.
Field-deployable chemical warfare agent detector. Continuous screening and on-site confirmation in one handheld unit. Exceptional sensitivity (ppb to sub-ppb, pg to ng range) in a handheld field instrument. No carrier gas. No radioactive source. Designed for continuous monitoring with no detection gaps. AI-powered identification with calibrated confidence scores.
Breath-based cancer diagnostic system for lung and breast cancer early detection. Detects volatile organic compound (VOC) biomarkers in exhaled breath using the same proprietary detection methodology. The operational clinical validation that proves the underlying science works in a demanding real-world environment.
We are structured to engage with government program offices, defense primes, and investment partners through established formal pathways.
Detection methodology, instrument configuration, signal processing architecture, and AI inference pipeline are IP protected. Full technical specifications available to qualified partners under executed NDA.
SBIR Phase I/II applications in preparation targeting DoD CWMD, DHS S&T, and related federal programs. We are prepared to engage program officers and technical evaluators at any stage of the application process.
Consortium engagement with the Chemical and Biological Defense (CBD) program and MCDC is planned. r-Guard™ addresses documented CBRNE capability gaps consistent with stated DoD technology priority areas.
Full technical documentation — instrument architecture, sensitivity data, AI methodology, and experimental validation results — is available to qualified partners under a standard mutual NDA. Contact us to initiate.
We are open to licensing, co-development, and integration partnerships with defense prime contractors seeking to add CWA detection capability to existing platforms. Technology is designed for integration into UAV/UGV payloads and fixed-site monitoring systems.
Actively seeking co-founders with spectroscopy hardware, fiber optics, or medical device engineering backgrounds. If you have the technical depth to build what we have designed, we want to talk. See contact form on product pages.
We welcome inquiries from government program officers, defense prime contractors, UAV platform integrators, clinical research partners, and potential co-founders. Full technical documentation available under NDA.